title: [Efficacy of 4 kinds of triple strategy for Helicobacter pylori eradication].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of 4 kinds of triple strategy of Helicobacter pylori (Hp) eradication.
  
  
  METHODS
  A total of 307 patients who suffered from Hp infection, confirmed by rapid urease test (RUT) and 14C-urea breath test (UBT),were randomly divided into 4 groups. Each group had 80, 76, 77, and 74 patients respectively. Group A was treated with rabeprazole, clarithromycin, and furazolidone (RCF); Group B with ranitidine bismuth citrate, clarithromycin, and furazolidone (BCF); Group C with rabeprazole, amoxicillin, and furazolidone (RAF); while Group D with ranitidine bismuth citrate, amoxicillin, and furazolidone (BAF). Hp was detected by RUT and UBT at 4 weeks after later treatment.
  
  
  RESULTS
  Hp eradication rates of group A,B,C, and D were 90.0%,67.1%,62.3%,and 45.9%,respectively. The difference between Group A and Group B, Group A and Group C was significant (P<0.05). Eradication rate of Group B and C was higher than that of Group D (P<0.05). There was no statistical difference between the eradication rate of Group B and C, and among the side effects of the 4 groups.
  
  
  CONCLUSIONS
  The strategy of RCF was the best among the 4 triple strategy of Hp eradication, which can be used clinically.
authors.affiliation: Department of Gastroenterology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Li
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Wang
authors.forename: Shou-Rong
authors.initials: SR
authors.lastname: Shen
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage; D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D017291:Clarithromycin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000382:microbiology*; D005260:Female; D005664:Furazolidone / Q000008:administration & dosage; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D064750:Rabeprazole; D013276:Stomach Ulcer / Q000382:microbiology*; D055815:Young Adult
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D064750:Rabeprazole; D005664:Furazolidone; D017291:Clarithromycin